Basic Information
| LncRNA/CircRNA Name | FOXD3-AS1 |
| Synonyms | FOXD3-AS1, pasFOXD3 |
| Region | GRCh38_1:63320884-63324441 |
| Ensemble | ENSG00000230798 |
| Refseq | NR_121634 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | neuroblastoma |
| ICD-0-3 | NA |
| Methods | RNA-seq, qPCR, Western blot, Luciferase reporter assay, in vitro knockdown, RIP etc. |
| Sample | cell lines (NB-1643, SK-N-BE(2), NB-1691, IMR32,BE(2)-C, SK-N-AS, SH-SY5Y, SK-N-SH), NB tissue |
| Expression Pattern | down-regulated |
| Function Description | FOXD3-AS1 is downregulated in NB tissues and cell lines, and ectopic expression of FOXD3-AS1 induces neuronal differentiation and decreases the aggressiveness of NB cells in vitro and in vivo.Mechanistically, as a nuclear lncRNA, FOXD3-AS1 interacts with poly(ADP-ribose) polymerase 1 (PARP1) to inhibit the poly(ADP-ribosyl)ation and activation of CCCTC-binding factor (CTCF), resulting in derepressed expression of downstream tumor-suppressive genes. FOXD3-AS1 harbors tumor-suppressive properties by inhibiting the oncogenic roles of PARP1 or CTCF and plays crucial roles in all-trans-retinoic-acid-mediated therapeutic effects on NB. |
| Pubmed ID | 29398485 |
| Year | 2018 |
| Title | Risk-Associated Long Noncoding RNA FOXD3-AS1 Inhibits Neuroblastoma Progression by Repressing PARP1-Mediated Activation of CTCF |
External Links
| Links for FOXD3-AS1 | GenBank HGNC NONCODE |
| Links for neuroblastoma | OMIM COSMIC |